Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro‐inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We recruited 150 consecutive patients ≥80 years old admitted to an orthogeriatric unit for an osteoporotic hip fracture. Muscle mass was assessed pre‐operatively using bioelectrical impedance analysis; Janssen's (J) and Masanés' (M) reference cut‐off points were used to define low muscle mass. Muscle strength was assessed with handgrip strength (Jamar's dynamometer). Sarcopenia was defined by having both low muscle mass and strength and using the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia (low grip strength). Peripheral markers—pro‐inflammatory and oxidative stress parameters—were determined either in the plasma or in the erythrocyte fraction obtained from peripheral whole blood of every patient pre‐operatively.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Mean age was 87.6 ± 4.9 years, and 78.7% were women. The prevalence of sarcopenia was 11.5% with Janssen's, 34.9% with Masanés' cut‐offs, and 93.3% with the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia. Among the four pro‐inflammatory cytokines tested in plasma, only tumour necrosis factor‐α was different (lower) in sarcopenic than in non‐sarcopenic participants using both muscle mass cut‐offs (J 7.9 ± 6.2 vs. 8.3 ± 5.8, M 6.8 ± 4.7 vs. 9.1 ± 6.2). Erythrocyte glutathione system showed a non‐significant tendency to lower glutathione levels and glutathione/oxidized glutathione ratios in sarcopenic participants compared with non‐sarcopenic subjects. Catalase activity was also lower in sarcopenic participants (J 2904 ± 1429 vs. 3329 ± 1483, M 3037 ± 1430 vs. 3431 ± 1498). No significant differences were found between groups in chymotrypsin‐like activity of the 20S proteasome, superoxide dismutase, glutathione peroxidase and butyrylcholinesterase activity, C‐terminal agrin fragment, interferon‐γ, or interleukin‐1β.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The prevalence of sarcopenia in patients with hip fracture varies according to the definition and the muscle mass reference cut‐off points used. We did not find differences in most neuromuscular, pro‐inflammatory, or oxidative stress markers, except for lower peripheral tumour necrosis factor‐α levels and catalase activity in sarcopenic participants, which may be markers of an early inflammatory reaction that is hampered in sarcopenic patients.</p></section>

A Pilot Study on Circulating, Cellular, and Tissue Biomarkers in Osteosarcopenic Patients

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

A Machine-Learning Approach to Target Clinical and Biological Features Associated with Sarcopenia: Findings from Northern and Southern Italian Aging Populations

Discovering the Individualized Factors Associated with Sarcopenia and Sarcopenic Obesity Phenotypes—A Machine Learning Approach

Nutritional and Nutrition-Related Biomarkers as Prognostic Factors of Sarcopenia, and Their Role in Disease Progression

The Biological Foundations of Sarcopenia: Established and Promising Markers

Identification of Novel Pathways and Immune Profiles Related to Sarcopenia

From a solitary blood-derived biomarker to combined biomarkers of sarcopenia: Experiences from the Korean Frailty and Aging Cohort Study

Blood biomarkers for sarcopenia: A systematic review and meta-analysis of diagnostic test accuracy studies

Integrating Transcriptomic and Proteomic Data for a Comprehensive Molecular Perspective on the Association between Sarcopenia and Osteoporosis

Sarcopenia: assessment of disease burden and strategies to improve outcomes

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Biomarkers of sarcopenia in very old patients with hip fracture

Circulating lumican as a potential biomarker for osteosarcopenia in older adults

Sarcopenia and bone health: new acquisitions for a firm liaison

Treating Sarcopenia in Older and Oldest Old

Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force

Sarcopenia: an overview

Novel metabolic and lipidomic biomarkers of sarcopenia

C‐Reactive Protein Level as a Novel Serum Biomarker in Sarcopenia

Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study